Biomanufacturing human pluripotent stem cells for therapeutic applications

Xiaojun Lian, Sean P. Palecek

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (iPSCs) can be propagated indefinitely and have the potential to differentiate to all cell types of the body. In addition, patient-specific human iPSCs and hESCs containing point mutations in genes that cause disease can be used to study diseases that have no adequate human in vitro or animal models. Harnessing the potential of these cells holds promise for future applications in cell therapy and regenerative medicine. Common methods of expanding and differentiating human pluripotent stem cells (hPSCs), including hESC and iPSC, require serum, mouse or human feeder cells, or feeder-conditioned medium. These methods are labor intensive and hard to scale, and sources of variability including growth factor fluctuations during preparation and culture complicate large-scale hPSC bioprocesses. Biomanufacturing cells from hPSCs requires development of fully defined, xeno-free culture medium and substrates formulated with human-derived, human recombinant proteins or chemically synthetic substrates under cGMP and improved processes for monitoring cell status and genomic stability during expansion and differentiation. In addition, robust and scalable differentiation methods must be developed. This chapter discusses recent progress and remaining challenges facing production of hPSC-derived cells.

Original languageEnglish (US)
Title of host publicationAdvances in Stem Cell Research
PublisherHumana Press Inc.
Pages29-48
Number of pages20
ISBN (Electronic)9781617799402
ISBN (Print)9781617799396
DOIs
StatePublished - Jan 1 2012

Fingerprint

Pluripotent Stem Cells
Stem cells
Induced Pluripotent Stem Cells
Therapeutics
Feeder Cells
Regenerative Medicine
Genomic Instability
Conditioned Culture Medium
Cell- and Tissue-Based Therapy
Point Mutation
Recombinant Proteins
Culture Media
Substrates
Intercellular Signaling Peptides and Proteins
Cell culture
Animal Models
Animals
Genes
Personnel
Serum

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Lian, X., & Palecek, S. P. (2012). Biomanufacturing human pluripotent stem cells for therapeutic applications. In Advances in Stem Cell Research (pp. 29-48). Humana Press Inc.. https://doi.org/10.1007/978-1-61779-940-2_3
Lian, Xiaojun ; Palecek, Sean P. / Biomanufacturing human pluripotent stem cells for therapeutic applications. Advances in Stem Cell Research. Humana Press Inc., 2012. pp. 29-48
@inbook{d90e9b48a0474b8fb53fa912105e42a2,
title = "Biomanufacturing human pluripotent stem cells for therapeutic applications",
abstract = "Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (iPSCs) can be propagated indefinitely and have the potential to differentiate to all cell types of the body. In addition, patient-specific human iPSCs and hESCs containing point mutations in genes that cause disease can be used to study diseases that have no adequate human in vitro or animal models. Harnessing the potential of these cells holds promise for future applications in cell therapy and regenerative medicine. Common methods of expanding and differentiating human pluripotent stem cells (hPSCs), including hESC and iPSC, require serum, mouse or human feeder cells, or feeder-conditioned medium. These methods are labor intensive and hard to scale, and sources of variability including growth factor fluctuations during preparation and culture complicate large-scale hPSC bioprocesses. Biomanufacturing cells from hPSCs requires development of fully defined, xeno-free culture medium and substrates formulated with human-derived, human recombinant proteins or chemically synthetic substrates under cGMP and improved processes for monitoring cell status and genomic stability during expansion and differentiation. In addition, robust and scalable differentiation methods must be developed. This chapter discusses recent progress and remaining challenges facing production of hPSC-derived cells.",
author = "Xiaojun Lian and Palecek, {Sean P.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-1-61779-940-2_3",
language = "English (US)",
isbn = "9781617799396",
pages = "29--48",
booktitle = "Advances in Stem Cell Research",
publisher = "Humana Press Inc.",

}

Lian, X & Palecek, SP 2012, Biomanufacturing human pluripotent stem cells for therapeutic applications. in Advances in Stem Cell Research. Humana Press Inc., pp. 29-48. https://doi.org/10.1007/978-1-61779-940-2_3

Biomanufacturing human pluripotent stem cells for therapeutic applications. / Lian, Xiaojun; Palecek, Sean P.

Advances in Stem Cell Research. Humana Press Inc., 2012. p. 29-48.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Biomanufacturing human pluripotent stem cells for therapeutic applications

AU - Lian, Xiaojun

AU - Palecek, Sean P.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (iPSCs) can be propagated indefinitely and have the potential to differentiate to all cell types of the body. In addition, patient-specific human iPSCs and hESCs containing point mutations in genes that cause disease can be used to study diseases that have no adequate human in vitro or animal models. Harnessing the potential of these cells holds promise for future applications in cell therapy and regenerative medicine. Common methods of expanding and differentiating human pluripotent stem cells (hPSCs), including hESC and iPSC, require serum, mouse or human feeder cells, or feeder-conditioned medium. These methods are labor intensive and hard to scale, and sources of variability including growth factor fluctuations during preparation and culture complicate large-scale hPSC bioprocesses. Biomanufacturing cells from hPSCs requires development of fully defined, xeno-free culture medium and substrates formulated with human-derived, human recombinant proteins or chemically synthetic substrates under cGMP and improved processes for monitoring cell status and genomic stability during expansion and differentiation. In addition, robust and scalable differentiation methods must be developed. This chapter discusses recent progress and remaining challenges facing production of hPSC-derived cells.

AB - Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (iPSCs) can be propagated indefinitely and have the potential to differentiate to all cell types of the body. In addition, patient-specific human iPSCs and hESCs containing point mutations in genes that cause disease can be used to study diseases that have no adequate human in vitro or animal models. Harnessing the potential of these cells holds promise for future applications in cell therapy and regenerative medicine. Common methods of expanding and differentiating human pluripotent stem cells (hPSCs), including hESC and iPSC, require serum, mouse or human feeder cells, or feeder-conditioned medium. These methods are labor intensive and hard to scale, and sources of variability including growth factor fluctuations during preparation and culture complicate large-scale hPSC bioprocesses. Biomanufacturing cells from hPSCs requires development of fully defined, xeno-free culture medium and substrates formulated with human-derived, human recombinant proteins or chemically synthetic substrates under cGMP and improved processes for monitoring cell status and genomic stability during expansion and differentiation. In addition, robust and scalable differentiation methods must be developed. This chapter discusses recent progress and remaining challenges facing production of hPSC-derived cells.

UR - http://www.scopus.com/inward/record.url?scp=84875154402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875154402&partnerID=8YFLogxK

U2 - 10.1007/978-1-61779-940-2_3

DO - 10.1007/978-1-61779-940-2_3

M3 - Chapter

AN - SCOPUS:84875154402

SN - 9781617799396

SP - 29

EP - 48

BT - Advances in Stem Cell Research

PB - Humana Press Inc.

ER -

Lian X, Palecek SP. Biomanufacturing human pluripotent stem cells for therapeutic applications. In Advances in Stem Cell Research. Humana Press Inc. 2012. p. 29-48 https://doi.org/10.1007/978-1-61779-940-2_3